These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16302717)

  • 1. [Treatment of precocious puberty by GnRH agonists].
    Carel JC
    Ann Urol (Paris); 2005 Oct; 39 Suppl 3():S85-8. PubMed ID: 16302717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty.
    Carel JC; Roger M; Ispas S; Tondu F; Lahlou N; Blumberg J; Chaussain JL
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1973-8. PubMed ID: 10372696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Triptorelin 3-Month Depot Compared to 1-Month Depot for the Treatment of Korean Girls with Central Precocious Puberty in Single Tertiary Center.
    Chung LY; Kang E; Nam HK; Rhie YJ; Lee KH
    J Korean Med Sci; 2021 Aug; 36(34):e219. PubMed ID: 34463062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
    Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE
    J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Triptorelin 3-Month Formulation in Chinese Children with Central Precocious Puberty: A Phase 3, Open-Label, Single-Arm Study.
    Luo X; Zhang C; Yang Y; Xu X; Cheng X; Wei H; Wang L; Huang F; Shi X; Cabri P
    Adv Ther; 2023 Oct; 40(10):4574-4588. PubMed ID: 37584898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison between complete and incomplete suppression of the hypophyseal-gonadal axis in girls with central precocious puberty: effect on growth and prospective final height].
    Partsch CJ; Hümmelink R; Sippell WG; Oostdijk W; Odink RJ; Drop SL
    Monatsschr Kinderheilkd; 1993 Dec; 141(12):935-9. PubMed ID: 8114776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of complete and incomplete suppression of pituitary-gonadal activity in girls with central precocious puberty: influence on growth and predicted final height. The German-Dutch Precocious Puberty Study Group.
    Partsch CJ; Hümmelink R; Peter M; Sippell WG; Oostdijk W; Odink RJ; Drop SL
    Horm Res; 1993; 39(3-4):111-7. PubMed ID: 8262471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty.
    Carel JC; Blumberg J; Seymour C; Adamsbaum C; Lahlou N;
    Eur J Endocrinol; 2006 Jan; 154(1):119-24. PubMed ID: 16382000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idiopathic precocious puberty versus puberty in adopted children; auxological response to gonadotrophin-releasing hormone agonist treatment and final height.
    Kempers MJ; Otten BJ
    Eur J Endocrinol; 2002 Nov; 147(5):609-16. PubMed ID: 12444892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty.
    Arrigo T; Cisternino M; Galluzzi F; Bertelloni S; Pasquino AM; Antoniazzi F; Borrelli P; Crisafulli G; Wasniewska M; De Luca F
    Eur J Endocrinol; 1999 Aug; 141(2):140-4. PubMed ID: 10427157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and treatment of central precocious puberty--can final height be improved? German/Dutch Central Precocious Puberty Study Group.
    Sippell WG
    Horm Res; 1994; 41 Suppl 2():14-5. PubMed ID: 8088698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results with a slow-release gonadotrophin-releasing hormone agonist in central precocious puberty. Dutch-German Precocious Puberty Study Group.
    Oostdijk W; Drop SL; Odink RJ; Hümmelink R; Partsch CJ; Sippell WG
    Acta Paediatr Scand Suppl; 1991; 372():39-45; discussion 46. PubMed ID: 1833950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of gonadotropin releasing hormone analogue therapy on girls with gonadotropin-dependent precocious puberty.
    Tung YC; Lee JS; Tsai WY; Hsiao PH
    J Formos Med Assoc; 2007 Oct; 106(10):826-31. PubMed ID: 17964961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth, bone maturation and height prediction after three years of therapy with the slow release GnRH-agonist Decapeptyl-Depot in children with central precocious puberty.
    Hümmelink R; Oostdijk W; Partsch CJ; Odink RJ; Drop SL; Sippell WG
    Horm Metab Res; 1992 Mar; 24(3):122-6. PubMed ID: 1533604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Growth, development and prediction of body height in children with central precocious puberty after 3 years of therapy with Decapeptyl-Depot, a slow-releasing GnRH agonist].
    Hümmelink R; Oostdijk W; Partsch CJ; Odink RJ; Drop SL; Sippell WG
    Cesk Pediatr; 1994; 49(1):7-12. PubMed ID: 8124755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors determining normal adult height in girls with gonadotropin-dependent precocious puberty treated with depot gonadotropin-releasing hormone analogs.
    Brito VN; Latronico AC; Cukier P; Teles MG; Silveira LF; Arnhold IJ; Mendonca BB
    J Clin Endocrinol Metab; 2008 Jul; 93(7):2662-9. PubMed ID: 18460564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged vaginal bleeding during central precocious puberty therapy with a long-acting gonadotropin-releasing hormone agonist.
    Yeshaya A; Kauschansky A; Orvieto R; Varsano I; Nussinovitch M; Ben-Rafael Z
    Acta Obstet Gynecol Scand; 1998 Mar; 77(3):327-9. PubMed ID: 9539281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of combined Gn-RH agonist and hGH therapy for better attining the goals in precocious puberty treatment.
    Tatò L; Saggese G; Cavallo L; Antoniazzi F; Corrias A; Pasquino AM; Cisternino M
    Horm Res; 1995; 44 Suppl 3():49-54. PubMed ID: 8719441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs.
    Lanes R; Soros A; Jakubowicz S
    J Pediatr Endocrinol Metab; 2004 May; 17(5):759-66. PubMed ID: 15237711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical study of subcutaneous administration of gonadotropin-releasing hormone agonist every six weeks in girls with idiopathic central precocious puberty].
    Liang Y; Wei H; Zhang JL; Hou L; Luo XP
    Zhonghua Er Ke Za Zhi; 2004 Nov; 42(11):845-9. PubMed ID: 15631714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.